Skip to main content Skip to main navigation menu Skip to site footer

TNF-α inhibitor administration in psoriatic arthritis patient with latent tuberculosis and cardiovascular disease as an extra articular manifestation

  • Nurrakhmadaniyah ,
  • Lita Diah Rahmawati ,


Introduction: Psoriatic arthritis is a spondyloarthropathy subtype with a broad clinical spectrum and diverse symptoms. The use of biological disease-modifying antirheumatic medications (DMARDs), such as TNF inhibitors is recommended as pharmacological therapy for PSA in cases of axial involvement and high disease activity level. Since Indonesia has the second-highest tuberculosis (TB) cases globally, and patients receiving TNF inhibitors have an elevated risk of latent TB reactivation, evaluation of latent TB before starting TNFi is necessary and challenging.

Case Presentation: A 63-year-old male psoriatic arthritis patient with bilateral hip joint osteoarthritis, bilateral knee effusions and bilateral frozen shoulder. The patient also had coronary heart disease with a history of underwent coronary artery bypass graft (CABG), diabetes mellites type 2 and confirmed latent TB. Psoriatic arthritis had high activity based on the Bath Ankylosing Spondylitis Disease Activity (BASDAI) score and Ankylosing Spondylitis Disease Activity Score (ASDAS). TNF inhibitor treatment started a month after latent TB treatment. The patient responded satisfactorily to the TNFi treatment, as demonstrated by clinical evaluation and decreased disease activity. Latent TB treatment was continued for up to six months, followed by latent TB activity monitoring during TNFi administration to prevent latent TB reactivation.

Conclusion: This case highlights the challenges in management of axial psoriatic arthritis patients with high disease activity, concomitant latent TB infection, and early extra-articular symptoms of cardiovascular disease.


  1. Awalia A, Satyadi S, Wibisono S, Soeroso J. Arterial Stiffness In Rheumatoid Arthritis Patients: Do Disease Activity And Duration Of Illness Matter? [Internet]. Abstracts Accepted for Publication. BMJ Publishing Group Ltd and European League Against Rheumatism; 2019. Available from:
  2. Smith JA, Colbert RA. Review: The interleukin-23/interleukin-17 axis in spondyloarthritis pathogenesis: Th17 and beyond. Arthritis Rheumatol (Hoboken, NJ) [Internet]. 2014 Feb;66(2):231–41. Available from:
  3. Rudwaleit M, van der Heijde D, Landewe R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis [Internet]. 2010;70(1):25–31. Available from:
  4. Cantini F, Niccoli L, Nannini C, Kaloudi O, Bertoni M, Cassarà E. Psoriatic arthritis: a systematic review. Int J Rheum Dis [Internet]. 2010;13(4):300–17. Available from:
  5. Feld J, Chandran V, Haroon N, Inman R, Gladman D. Axial disease in psoriatic arthritis and ankylosing spondylitis: a critical comparison. Nat Rev Rheumatol. 2018;14(6):363-371. doi: 10.1038/s41584-018-0006-8. PMID: 29752461.
  6. Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D. European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update. Ann Rheum Dis. 2016;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337.
  7. Rahmawati LD, Soeroso J, Aryati. The roles of Single Nucleotide Polymorphism (SNP) Endoplasmic Reticulum Aminopeptidase 1 (ERAP 1) gene in axial spondyloarthritis Indonesian adults. Ann Med Surg [Internet]. 2022 Apr 28;77:103675. Available from:
  8. Yuliasih Y, Lanasakti Y. IL-17 and Disease Activity in Spondyloarthitis. Folia Medica Indones [Internet]. 2021;57(4):289. Available from:
  9. Kragstrup TW, Andersen T, Heftdal LD, Hvid M, Gerwien J, Sivakumar P, et al. The IL-20 Cytokine Family in Rheumatoid Arthritis and Spondyloarthritis. Front Immunol [Internet]. 2018 Sep 25;9:2226. Available from:
  10. Sieper J, van der Heijde D, Landewe R, Brandt J, Burgos-Vagas R, Collantes-Estevez E, et al. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). Ann Rheum Dis [Internet]. 2009;68(6):784–8. Available from:
  11. Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: Development of new criteria from a large international study. Arthritis & Rheum [Internet]. 2006;54(8):2665–73. Available from:
  12. Langley RGB, Krueger GG, Griffiths CEM. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis [Internet]. 2005 Mar;64 Suppl 2(Suppl 2):ii18–25. Available from:
  13. Nguyen C V, Farah RS, Maguiness SM, Miller DD. Follicular Psoriasis: Differentiation from Pityriasis Rubra Pilaris-An Illustrative Case and Review of the Literature. Pediatr Dermatol [Internet]. 2016;34(1):e65–8. Available from:
  14. Negera E, Walker SL, Girma S, Doni SN, Tsegaye D, Lambert SM, et al. Clinico-pathological features of erythema nodosum leprosum: A case-control study at ALERT hospital, Ethiopia. PLoS Negl Trop Dis [Internet]. 2017 Oct 13;11(10):e0006011–e0006011. Available from:
  15. Rath D, Bhargava S, Kundu BK. Leprosy mimicking common rheumatologic entities: a trial for the clinician in the era of biologics. Case Rep Rheumatol [Internet]. 2014/11/06. 2014;2014:429698. Available from:
  16. Center for Health Data and Information Ministry of RI. Eliminate Stigma and Discrimination against Leprosy. Jakarta: Infodatin. 2015.
  17. Owlia MB, Mostafavi Pour Manshadi SMY, Naderi N. Cardiac manifestations of rheumatological conditions: a narrative review. ISRN Rheumatol [Internet]. 2012/10/17. 2012;2012:463620. Available from:
  18. van der Heijde D, Ramiro S, Landewé R, Baraliakos X, Van den Bosch F, Sepriano A, et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. Ann Rheum Dis [Internet]. 2017;76(6):978–91. Available from:
  19. Irons K, Harrison H, Thomas A, Martindale J, Jeffries C. The Bath Indices: Ankylosing Spondylitis. National Ankylosing Spondylitis Society (NASS). 2016:1-16.
  20. Nordgaard-Lassen I, Dahlerup JF, Belard E, Gerstoft J, Kjeldsen J, Kragballe K, Ravn P, Sørensen IJ, Theede K, Tjellesen L; Danish Society for Gastroenterology. Guidelines for screening, prophylaxis and critical information prior to initiating anti-TNF-alpha treatment. Dan Med J. 2012;59(7):C4480.
  21. Salgado E, Gómez-Reino JJ. The risk of tuberculosis in patients treated with TNF antagonists. Expert Rev Clin Immunol [Internet]. 2011;7(3):329–40. Available from:
  22. Soedarsono S. Tuberculosis: Development of New Drugs and Treatment Regimens. J Respirasi [Internet]. 2021;7(1):36. Available from:
  23. Chaudhary R, Bhatta S, Singh A, Pradhan M, Shrivastava B, Singh YI, et al. Diagnostic performance of GeneXpert MTB/RIF assay compared to conventional Mycobacterium tuberculosis culture for diagnosis of pulmonary and extrapulmonary tuberculosis, Nepal. Narra J [Internet]. 2021;1(2). Available from:

How to Cite

Nurrakhmadaniyah, & Rahmawati, L. D. . (2022). TNF-α inhibitor administration in psoriatic arthritis patient with latent tuberculosis and cardiovascular disease as an extra articular manifestation. Bali Medical Journal, 11(2), 856–863.




Search Panel

Google Scholar
BMJ Journal

Lita Diah Rahmawati
Google Scholar
BMJ Journal